OncoLink Cancer Treatment and Resources
Link to OncoLink

Preliminary Results of the GORTEC 96-01 Randomized Trial, Comparing Very Accelerated Radiotherapy Versus Concomitant Radio-Chemotherapy for Locally Inoperable HNSCC

William Levin, MD
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 5 de noviembre del 2001

Presenter: J. Bourhis
Presenter's Affiliation: Institut Gustave Roussy, Villejuif, France
Type of Session: Plenary

Background

  • There is some clinical evidence that radiation therapy administered over a shorter period of time offers better tumor control by decreasing the ability of cancer cells to repair themselves from radiation-induced damage.
  • Combined chemotherapy and radiation therapy regimens are also used in the treatment of advanced cancers.
  • It is unclear as to if one of these approaches is superior.

    Materials and Methods

  • Patients with advanced stage squamous cell cancer of the head and neck were randomized to receive either modified fractionated radiotherapy (RT) or concomitant radio-chemotherapy (RT-CT)
  • 109 patients were randomized between very accelerated RT (62-64 Gy/3weeks) and moderately accelerated RT (62-64 Gy/5 weeks) + CDDP 100 mg/m2 Days 1, 16 and 32 and 5FU 1g/m2/day, days 1 to 5 and 31 to 35.
  • In the RT-CT arm, 2 additional cycles of CDDP-5FU were given whenever possible, 28 days and 56 days after the local treatment.
  • 90% of patients had T4 tumors or N3 nodal disease.
  • The majority of patients had oropharynx cancer.

    Results

  • There was a 96% incidence of grade 3/4 mucositis in the Accelerated Group, versus 81% in the RT-CT Group.
  • For both groups, there was only about 30% locaregional control.
  • There was no significant difference between groups in terms of survival or incidence of distant metastases.

    Author's Conclusions

  • Accelerated radiotherapy is no better than chemoirradiation in terms of locoregional control, distant metastases, or overall survival.

    Clinical/Scientific Implications

  • Local control of advanced head and neck cancers is necassary before improvements in survival can be achieved.
  • Accordingly, the development of other chemotherapeutic and biologic therapies are needed.

    Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology and Pharmacia Oncology.

  • OncoLink I wish u knew...

    3D mammography, also known as digital tomosynthesis, is a new technology aimed at having better detection of abnormalities and fewer false positives. Read more.

    Cancer Types
    Bone Cancer
    Brain Tumors
    Breast Cancer
    Carcinoid Tumors
    Endocrine System Cancers
    Gastrointestinal Cancers
    Gynecologic Cancers
    Head and Neck Cancers
    Leukemia
    Lung Cancers
    Lymphomas
    Myelomas
    Pediatric Cancers
    Penile Cancer
    Prostate Cancer
    Sarcomas
    Skin Cancers
    Testicular Cancer
    Thyroid Cancer
    Urinary Tract Cancers
    OncoLink Vet

    Cancer Treatment
    Biologic Therapy
    Bone Marrow Transplants
    Chemotherapy

    Clinical Trials
    Complementary Medicine
    Gene Therapy
    General Treatment Concerns
    Hormone Therapy
    PDT Center
    Proton Therapy
    Radiation Oncology
    Surgical Oncology
    Targeted Therapies
    Vaccine Therapies

    Cancer Support
    Caregivers
    Hospice Care and Bereavement
    Nutrition and Cancer
    Sexuality & Fertility
    Side Effects
    Support
    Survivorship
    Exercise and Cancer

    Cancer Resources
    Cancer News
    OncoLink University
    Nurses' Notes
    Conferences
    Newly Diagnosed Patients
    Causes and Prevention
    Legal and Financial Information for Patients
    LGBT Resources
    NCI Resources
    Global Resources
    Cancer Resource List
    Resources for Young Adults

    OncoLink Media Library
    OncoLink TV
    Book, Music and Video Reviews


    Ask the Experts
    Brown Bag Chat
    Tracy's Corner

    About OncoLink
    About OncoLink
    Giving to OncoLink
    Contact Information
    Usage Policy
    Editorial Board
    How to Partner with OncoLink
    Link to OncoLink
    Mission Statement

    OncoLink Cancer Resources RSS What's New RSS